Treatment of infections caused by resistant Staphylococcus aureus

Methods in Molecular Biology

Volumn 391, Issue , 2007, Pages 227-258

  Anstead, Gregory M ^a   Quinones Nazario, Gabriel ^a   Lewis II, James S ^a  

^a NONE

Author keywords

Clindamycin; Daptomycin; Fosfomycin; Fusidic acid; Linezolid; Methicillin resistant S. Aureus; Vancomycin

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DRUG DERIVATIVE; LINEZOLID; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; HUMAN; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VIRGINIAMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 36549055035     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-468-0:227     Document Type: Article

References (116)

1. Lindsay, J. A. and Holden, M. T. G. (2004) Staphylococcus aureus: superbug, super genome? Trends Microbiol. 12, 378-385.
2. Naimi, T. S., LeDell, K. H., Como-Sabetti, K., et al. (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290, 2976-2984.
3. Rybak, M. J. and LaPlante, K. L. (2005) Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 25, 74-85.
4. Gilbert, D. N., Moellering, R. C., Eliopoulos, G. M., and Sande, M. A. (eds.). (2005) The Sanford Guide to Antimicrobial Therapy 2005, 35th ed., Antimicrobial Therapy, Hyde Park, VT.
5. Gosbell, I. B. (2005) Diagnosis and management of catheter-related bloodstream infections due to Staphylococcus aureus. Intern. Med. J. 35, S45-S62.
6. Davis, J. S. (2005) Management of bone and joint infections due to Staphylococcus aureus. Intern. Med. J. 35, S79-S96.
7. Murray, R. J. (2005) Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern. Med. J. 35, S25-S44.
8. Mitchell, D. H. and Howden, B. P. (2005) Diagnosis and management of Staphylococcus aureus bacteraemia. Intern. Med. J. 35, S17-S24.
9. Cosgrove, S. E., Carroll, K. C., and Perl, T. M. (2004) Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39, 539-545.
10. Anonymous. (2004) Vancomycin-resistance Staphylococcus aureus-New York, 2004. MMWR Morbid. Mortal. Wkly. Rep. 53, 322, 323.
11. Bozdogan, B., Esel, D., Whitener, C., Browne, F. A., and Appelbaum, P. C. (2004) Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52, 864-868.
12. Fiebelkorn, K. R., Crawford, S. A., McElmeel, M. L., and Jorgensen, J. H. (2003) Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J. Clin. Microbiol. 41, 4740-4744.
13. O'Brien, F. G., Zainin, Z., Coombs, G. W., Pearson, J. C., Christiansen, K., and Grabb, W. B. (2005) Macrolide, lincosamide and streptogramin B resistance in a dominant clone of Australian community methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 56, 985, 986.
14. Lewis, J. S. II and Jorgensen, J. H. (2005) Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 40, 280-285.
15. Siberry, G. K., Tekle, T., Carroll, K., and Dick, J. (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. 37, 1257-1260.
16. von Eiff, C., Lubritz, G., Heese, C., Peters, G., and Becker, K. (2004) Effect of trimethoprim-sulfamethoxazole in AIDS patients on the formation of the small colony variant phenotype of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 48, 191-194.
17. Levine, D. P. (2006) Vancomycin: a history. Clin. Infect. Dis. 42, S5-S12.
18. Kollef, M. H. and Micek, S. T. (2005) Staphylococcus aureus pneumonia: a "superbug" infection in community and hospital settings. Chest 128, 1093-1096.
19. Stevens, D. L. (2006) The role of vancomycin in the treatment paradigm. Clin. Infect. Dis. 42, S51-S57.
20. Rello, J., Torres, A., Ricart, M., Valles, J., Gonzalez, J., Artigas, A., and Rodriguez-Roisin, R. (1994) Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-sensitive and methicillin-resistant episodes. Am. J. Respir. Crit. Care Med. 150, 1545-1549.
21. Tice, A. D., Hoagland, P., and Shoultz, D. A. (2003) Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am. J. Med. 114, 723-728.
22. Chambers, H. F. (1997) Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections, in The Staphylococci in Human Disease (Crossley, K. B., and Archer, G. L., eds.), Churchill-Livingstone, New York, pp. 583-601.
23. Jones, R. N. (2006) Microbiologic features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42, S13-S24.
24. Rello, J. N., Sole-Violan, J., Sa-Borges, M., et al. (2005) Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. 33, 1983-1987.
25. American Thoracic Society, Infectious Diseases Society of America. (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416.
26. Rayner, C. and Munckhof, W. J. (2005) Antibiotic currently used in the treatment of infections caused by Staphylococcus aureus. Intern. Med. J. 35, S3-S16.
27. Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., and Wong-Beringer, A. (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166, 2138-2144.
28. Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., and Tenover, F C. (2003) Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36, 429-439.
29. Livermore, D. M. (2003) Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. S2), ii9-ii16.
30. Wunderink, R. G., Bello, J., Cammarata, S. K., Croos-Dadrera, R. V., and Kollef, M. H. (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124, 1789-1797.
31. Kollef, M. H., Relio, J., Cammarata, S. K., Croos-Dabrera, R. V., and Wunderink, R. G. (2004) Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing line-zolid with vancomycin. Intensive Care Med. 30, 388-394.
32. Ioanas, M. and Lode, H. (2004) Linezolid in VAP by MRSA: better choice? Intensive Care Med. 30, 343-346.
33. Honeybourne, D., Tobin, C., Jevons, G., Andrews, J., and Wise, R. (2003) Intrapulmonary penetration of linezolid. J. Antimicrob. Chemother. 51, 1431-1434.
34. Micek, S. T., Dunne, M., and Kollef, M. H. (2005) Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128, 2732-2738.
35. Francis, J. S., Doherty, M. C., Lopatin, U., et al. (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine Leukocidin genes. Clin. Infect. Dis. 40, 100-107.
36. Shukla, S. K. (2005) Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin. Med. Res. 3, 57-60.
37. Geminei, C. G. and Ford, C. W. (2002) Virulence factor expression by Grampositive cocci exposed to subinhibitory concentrations of linezolid. J. Antimicrob. Chemother. 50, 667-672.
38. Bernardo, K., Pakulat, N., Fleer, S., et al. (2004) Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob. Agents Chemother. 48, 544-546.
39. Rayner, C. R., Baddour, L. M., Birmingham, M. C., Norden, C., Meagher, A. K., and Schetag, J. J. (2004) Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 32, 8-14.
40. Kutscha-Lissberg, F., Hebler, U., Muhr, G., and Koller, M. (2003) Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47, 3964-3966.
41. Lipsky, B. A., Itani, K., and Norden, C. (2004) Linezolid Diabetic Foot Infection Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38, 17-24.
42. Kaplan, S. L., Afghani, B., Lopez, P., et al. (2003) Linezolid for the treatment of methicillin-resistant Staphylococcus aureus in children. Pediatr. Infect. Dis. J. 22, S178-S185.
43. Shorr, A. F., Kunkek, M. J., and Kollef, M. (2005) Linezolid versus vancomycin for Staphylococcus aureus baeteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56, 923-929.
44. Sharpe, J. N., Shively, M. D., and Polk, H. C. Jr. (2005) Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 189, 425-428.
45. Weigelt, J., Kaafarani, H. M. A., Itani, K. M. F., and Swanson, R. N. (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188, 760-766.
46. Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C., and Linezolid CSSTI Study Group. (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49, 2260-2266.
47. Howden, B. P., Charles, P. G. P., Johnson, P. D. R., Ward, P. B., and Grayson, M. L. (2005) Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drag or reduced vancomycin susceptibility? Antimicrob. Agents Chemother. 419, 4816, 4817.
48. Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., and Moellering, R. C. Jr. (2004) Accessory gene regulatory group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38, 1700-1705.
49. Clinical and Laboratory Standards Institute/NCCLS. (2006) Performance Standards for Antimicrobial Susceptibility Testing, Supplement M100-S16, Clinical and Laboratory Standards Institute, Wayne, PA.
50. Sancak, B., Ercis, S., Menemenlioglu, D., Çolakoglu S., and Hasçelik, G. (2005) Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother. 56, 519-523.
51. Liu, C. and Chambers, H. F. (2003) Staphylococcus aureus with heterogeneous resistance to vancomycin: clinical significance and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47, 3040-3045.
52. Nasraway, S. A., Shorr, A. F., Kuter, D. J., O'Grady, N., Le, V. H., and Cammarata, S. K. (2003) Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. 37, 1609-1616.
53. Rao, N., Ziran, B. H., Wagener, M. M., Santa, E. R., and Yu, V. L. (2004) Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic devices. Clin. Infect. Dis. 38, 1058-1064.
54. Bergeron, L., Boulé, M., and Perreault, S. (2005) Serotonin toxicity associated with concomitant use of linezolid. Ann. Pharmacother. 39, 956-961.
55. Anonymous. (2004) Pfizer: Zyvox (linezolid). Safety-nervous-psychiatric. Reports of peripheral or optic neuropathy. Data on file.
56. Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., and Schentag, J. J. (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36, 159-168.
57. Legout, L., Senneville, E., Gomel, J. J., Yazdanpanah, Y., and Mouton, Y. (2004) Linezolid-induced neuropathy. Clin. Infect. Dis. 38, 767, 768.
58. Frippiat, F., Bergiers, C., Michel, C., Dujardin, J. P., and Derue, G. (2004) Severe bilateral optic neuritis associated with prolonged linezolid therapy. J. Antimicrob. Agents Chemother. 53, 114, 115.
59. Ferry, T., Ponceau, B., Simon, M., et al. (2005) Possibly linezolid-induced peripheral and central nervous system neurotoxicity: report of four cases. Infection 33, 151-154.
60. Shorr, A. F., Susla, G. M., and Kollef, M. H. (2004) Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit. Care Med. 32, 137-143.
61. Machado, A. R., Arns Cda, C., Follador, W., and Guerra, A. (2005) Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz. J. Infect. Dis. 9, 191-200.
62. Li, J. Z., Willke, R. J., Rittenhouse, B. E., and Rybak, M. J. (2003) Effect of line-zolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg. Infect. 4, 45-58.
63. Draghi, D. C., Sheehan, D. J., Hogan, P., and Sahm, D. F (2005) In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 Surveillance Program. Antimicrob. Agents Chemother. 49, 5024-5032.
64. Streit, J. M., Jones, R. N., Sader, H. S., and Fritsche, T. R. (2004) Assessment of pathogen occurrence and resistance profiles among infected patients in the intensive care unit report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents 24, 11-18.
65. Hoban, D. J., Bouchillon, S. K., Johnson, B. M., Johnson, J. L., and Dowzicky, M. J. (2005) In vitro activity of tigecycline against 6792 Gram-negative and Grampositive clinical isolates from global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52, 215-227.
66. Lomaestro, B. M. (2003) Resistance to linezolid. Are we surprised? How hard should we look? Ann. Pharmacother. 37, 909-911.
67. Fenton, C., Keating, G. M., and Curran, M. P. (2004) Daptomycin. Drugs 64, 445-455.
68. Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., and Daptomycin 98-01 and 99-01 Investigators. (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673-1681.
69. Alder, J. D., Thorne, G., Luperchio, S., Anastasiou, D., Eisenstein, B., and Tally, F. (2003) Daptomycin compared to semi-synthetic penicillins or vancomycin for treatment of complicated skin and skin structure infections (cSSSI) caused by S. aureus [abstract 296], in Program and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America, (Sears, C. L., Karp, C. L. (eds.), Alexandria, VA. p. 83.
70. Echevarria, K., Datta, P., Cadena, J., and Lewis, J. S. II (2005) Severe myopathy and possible hepatotoxicity related to daptomycin. J. Antimicrob. Chemother. 55, 599, 600.
71. Hayden, M. K., Rezai, K., Hayes, R. A., Lolans, K., Quinn, J. P., and Weinstein, R. A. (2005) Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43, 5285-5287.
72. Fowler, V. G. Jr., Boucher, H. W., Corey, G. R., et al., S. aureus Endocarditis and Bacteremia study Group. (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New Eng. J. med. 355, 653-665.
73. Sakoulas, G., Eliopoulos, G. M., Alder, J., and Eliopoulos, C. T. (2003) Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1714-1718.
74. Tsuji, B. T. and Rybak, M. J. (2005) Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49, 2735-2745.
75. Rand, K. H. and Houck, H. J. (2004) Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48, 2871-2875.
76. Klastersky, J. (2003) Role of quinupristin/dalfopristin in the treatment of Grampositive nosocomial infections in haematological or oncological patients. Cancer Treat. Rep. 29, 431-440.
77. Mabe, S. and Champney, W. S. (2005) A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. Curr. Microbiol. 51, 363-366.
78. Breedt, J., Teras, J., Gardovskis, J., et al., and Tigecycline 305 cSSSI study Group. (2005) Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycinaztreonam. Antimicrob. Agents Chemother. 49, 4658-4666.
79. Allen, N. E. and Nicas, T. I. (2003) Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511-532.
80. Mercier, R.-C., Houlihan, H. H., and Rybak, M. J. (1997) Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41, 1307-1312.
81. Giamarellou, IL, O'Riordan, W., Harris, H., Owen, S., Porter, S. B., and Loutit, J. S. (2003) Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739a], in Program and Abstracts of the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC.
82. Wasilewski, M., Disch, D., McGill, J., Harris, H., O'Riordan, W., and Zeckel, M. (2001) Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin-skin structure infections (cSSSI) [abstract UL-IS], in Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC.
83. van Bambeke, F., van Laethem, Y., Courvalin, P., and Tulkens, P. (2004) Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64, 913-936.
84. Leighton, A., Gottlieb, A. B., Don-, M. B., et al. (2004) Tolerability, pharma-cokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48, 940-945.
85. Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., and Dalbavancin Skin and Soft-Tissue Infection Study Group. (2003) Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37, 1298-1303.
86. Vicuron Pharmaceuticals. (2004) Press release. Vicuron Pharmaceuticals announces positive pivotal phase III results for dalbavancin in skin and soft tissue infections. Accessed August 12, 2004. http://biz.yahoo.com/prnews/040812/ sfth039_1.html.
87. Jauregui, L. E., Babazadeh, S., Seltzer, E., et al. (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41, 1407-1415.
88. Bogdanovich, T., Ednie, L. M., Shapiro, S., and Appelbaum, P. C. (2005) Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49, 4210-4219.
89. Guignard, B., Entenza, J. M., and Moreillon, P. (2005) β-lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 5, 479-489.
90. Reyes, N., Skinner, R., Kaniga, K., et al. (2005) Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 4344-4346.
91. McCollum, M., Rhew, D. C., and Parodi, S. (2003) Cost analysis of switching from IV vancomycin to po linezolid for the management of methicillin-resistant Staphylococcus species. Clin. Ther. 25, 3173-3189.
92. Itani, K. M. F., Weigelt, J., Li, J. Z., and Duttagupta, S. (2005) Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 26, 442-448.
93. Jorgensen, J. H. and Fiebelkorn, K. (2006) Susceptibility of Common Organisms. January-December 2005, University Health System, San Antonio, TX.
94. Reynolds, R., Potz, N., Colman, M., Williams, A., Livermore, D., MacGowan, A., and BSAC Extended Working Party on Bacteraemic Resistance Surveillance. (2004) Antimicrobial susceptibility of the pathogens of bacteraemia in UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. 53, 1018-1032.
95. Yuk, J. H., Dignani, M. C., Harris, R. L., Bradshaw, M. W., and Williams, T. W. Jr. (1991) Minocycline as an alternative antistaphylococcal agent. Rev. Infect. Dis. 13, 1023, 1024.
96. Ruhe, J. J., Monson, T., Bradshear, R. W., and Menon, A. (2005) Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin. Infect. Dis. 40, 1429-1434.
97. Nicolau, D. P., Freeman, C. D., Nightingale, C. H., Coe, C. J., and Quintiliani, R. (1994) Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38, 1515-1518.
98. Levine, D. P., Fromm, B. S., and Reddy, B. R. (1991) Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphyloccoccus aureus endocarditis. Ann. Intern. Med. 115, 674-680.
99. Dailey, C. F., Pagano, P. J., Buchanan, L. V., Paquette, J. A., Haas, J. V., and Gibson, J. K. (2003) Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 47, 2655-2658.
100. Egle, H., Trittler, R., Kummerer, K., and Lemnien, S. W. (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin. Pharmacol. Ther. 77, 451-453.
101. Krat, O., Sommer, H., and Kronke, M. (2004) Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells. J. Antimicrob. Chemother. 53, 167-173.
102. Shopsin, B., Zhao, X., Kreiswirth, B. N., Tillotson, G. S., and Drlica, K. (2004) Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int. J. Antimicrob. Agents 24, 32-34.
103. Iyer, S. and Jones, D. H. (2004) Community-acquired methicillin-resistant skin infections: a retrospective analysis of clinical presentation and treatment of a local outbreak. J. Am. Acad Dermatol. 50, 854-858.
104. Grim, S. A., Rapp, R. P., Martin, C. A., and Evans, M. E. (2005) Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 25, 253-264.
105. Markowitz, N., Quinn, E. L., and Saravolatz, L. D. (1992) Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117, 390-398.
106. de Górgolas, M., Avilés, P., Vedejo, C., and Fernandez Guerrero, M. L. (1995) Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob. Agents Chemother. 39, 953-957.
107. Shams, W. E., McCormick, M., Rapp, R. P., and Evans, M. E. (2005) The use of trimethoprim-sulfamethoxazole for serious MRSA infections. Infect. Med. 22, 507-510.
108. Ellis, M. W. and Lewis, J. S. II. (2005) Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus. Curr. Opin. Infect. Dis. 18, 496-501.
109. Johnson, J. R. (2003) Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 36, 236, 237.
110. Stein, A., Bataille, J. F., Drancourt, M., Curvale, G., Argenson, J. N., Groulier, P., and Raoult, D. (1998) Ambulatory treatment of multi-drug resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob. Agents Chemother. 42, 3086-3091.
111. Howden, B. P. and Grayson, M. L. (2006) Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 42, 394-400.
112. Nimmo, G. R., Bell, J. M., Mitchell, D., Gosbell, I. B., Pearman, J. W., and Turnidge, J. D. (2003) Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999. Microb. Drug Resist. 9, 155-160.
113. Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A., and Allerberger, F. (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48, 209-217.
114. Hamilton-Miller, J. M. (1992) In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios 71, 95-103.
115. Pankey, G. A. and Sabath, L. D. (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38, 864-870.
116. Lee, M. C., Rios, A. M., Aten, M. F., Mejias, A., Cavuoti, D., McCracken, G. H., and Hardy, R. D. (2004) Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 23, 123-127.